Is the US prepared to deal with another pandemic or widespread health crisis?
The US is better prepared than before COVID-19 in several key areas due to investments, structural changes, and applied lessons, but it is not fully ready for another major pandemic or widespread health crisis. Significant gaps persist in coordination, sustained funding, workforce capacity, state/local readiness, and full implementation of reforms, leaving vulnerabilities that experts warn could lead to high human and economic costs. Assessments from government, bipartisan commissions, GAO, and others describe progress as real but incomplete and fragile.[1][2]
Key Improvements
Post-COVID efforts under the Biden-Harris Administration (and building on prior work) strengthened several pillars:
These changes helped mitigate later COVID waves and supported responses to subsequent threats. Vaccinations alone during COVID saved millions of US lives and hospitalizations, per analyses.
Persistent Gaps and Challenges
Experts consistently note that progress is uneven and incomplete:
The 2024 Bipartisan Commission Blueprint, GAO high-risk work, NEJM commentaries, and Stimson Center assessments converge on the view that the US has not fully learned or institutionalized COVID lessons, risking a repeat (or worse) of failures in detection, equitable response, clear guidance, and surge capacity.[2][8]
Overall Assessment
Preparedness is a spectrum, not binary. The US has stronger tools (stockpiles, surveillance, platforms, dedicated offices) and demonstrated capabilities in recent outbreaks than in early 2020. It ranks relatively highly on metrics like the Global Health Security Index historically and recent SPAR/JEE processes. However, structural, funding, coordination, workforce, and trust deficits mean it is not fully prepared for a high-impact novel pathogen, intentional biothreat, or concurrent crises. A severe event could still overwhelm systems, especially if it spreads faster/more lethally than COVID or hits vulnerable populations hard.
Experts (CDC testimony, commissions, GAO, former officials) emphasize continuous investment, full implementation of open recommendations, stronger SLTT support, clear authorities, domestic manufacturing, better One Health (human-animal-environment) integration, and rebuilding trust/communication. Progress is reversible without sustained political will and resources. Ongoing monitoring of threats like H5N1 serves as a real-world stress test revealing both advances and remaining weaknesses.[3][9]
In short: improved and more resilient than pre-COVID, but with critical unfinished business that leaves the nation exposed.
Citations (14)
- https://bidenwhitehouse.archives.gov/briefing-room/statements-releases/2025/01/14/report-the-biden-harris-administration-roadmap-for-pandemic-preparedness-and-response/
Backs: “Assessments from government, bipartisan commissions, GAO, and others describe progress as real but incomplete and fragile.”
- https://biodefensecommission.org/reports/the-national-blueprint-for-biodefense/
Backs: “Assessments from government, bipartisan commissions, GAO, and others describe progress as real but incomplete and fragile.”
- https://www.cdc.gov/washington/testimony/2024/t20241114.htm
Backs: “Tools like the Influenza Risk Assessment Tool (IRAT) help prioritize threats.”
- https://www.cdc.gov/readiness/php/next-gen-phep/index.html
Backs: “CDC reorganized around readiness frameworks (e.g., Public Health Response Readiness priorities for 2024–2028), emphasizing risk-based planning, partnerships, workforce, and data modernization. Dual-use research oversight was strengthened.”
- https://www.foreignaffairs.com/united-states/world-not-ready-next-pandemic
Backs: “Responses to mpox and H5N1 demonstrated deployment of vaccines/therapeutics.”
- https://iris.who.int/bitstream/handle/10665/380155/9789240105409-eng.pdf?sequence=1sask
Backs: “CDC and ASPR continue all-hazards preparedness via programs like PHEP.”
- https://extranet.who.int/sph/spar-united-states-america-submitted2024
Backs: “CDC and ASPR continue all-hazards preparedness via programs like PHEP.”
- https://www.nejm.org/doi/full/10.1056/NEJMp2406427
Backs: “The Bipartisan Commission on Biodefense’s 2024 National Blueprint stresses the need for stronger top-level leadership and calls the nation “dangerously vulnerable,” with fractionated activities insufficient despite prior recommendations.”
- https://www.stimson.org/2024/prepare-for-the-next-biothreat-now/
Backs: “The Bipartisan Commission on Biodefense’s 2024 National Blueprint stresses the need for stronger top-level leadership and calls the nation “dangerously vulnerable,” with fractionated activities insufficient despite prior recommendations.”
- https://www.gao.gov/products/gao-24-107175
Backs: “GAO and others document hundreds of COVID-related recommendations (roughly half unimplemented as of mid-to-late 2024 updates), including on testing strategies, data systems, isolation/quarantine planning, and program coordination (e.g., PHEP and Hospital Preparedness Program).”
- https://jamanetwork.com/journals/jama/fullarticle/2819159
Backs: “Broader issues include health inequities, chronic disease burdens (which amplify pandemic impacts), and supply-chain dependencies.”
- https://www.cidrap.umn.edu/smallpox/national-academies-report-says-us-not-ready-intentional-accidental-smallpox-outbreak
Backs: “Vaccine stockpiles for novel threats may cover only a tiny fraction of the population initially, requiring rapid scale-up.”
- https://reliefweb.int/attachments/c8c1aaeb-17fc-42af-a6a2-dc2f79aa8bb5/gpmb-2024-report.pdf
Backs: “Vaccine stockpiles for novel threats may cover only a tiny fraction of the population initially, requiring rapid scale-up.”
- https://www.cidrap.umn.edu/covid-19/gao-hhs-fix-persistent-deficiencies-infectious-disease-testing-next-pandemic
Backs: “Recent analyses note that while capacities improved, political attention and funding momentum have waned in places.”